Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab 3+PRN With or Without PRP for Diabetic Macular Edema
ChiCTR2500113346Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Retinal arteriovenous vascular diameter. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2500113346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113346.